Donepezil for mild cognitive impairment in Parkinson’s disease

Abstract We investigated the efficacy of donepezil for mild cognitive impairment in Parkinson’s disease (PD-MCI). This was a prospective, non-randomized, open-label, two-arm study. Eighty PD-MCI patients were assigned to either a treatment or control group. The treatment group received donepezil for...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kyoungwon Baik, Seon Myeong Kim, Jin Ho Jung, Yang Hyun Lee, Seok Jong Chung, Han Soo Yoo, Byoung Seok Ye, Phil Hyu Lee, Young H. Sohn, Seung Wan Kang, Suk Yun Kang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/39f7c08a31db49eb80b91afbe4c66e31
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:39f7c08a31db49eb80b91afbe4c66e31
record_format	dspace
spelling	oai:doaj.org-article:39f7c08a31db49eb80b91afbe4c66e312021-12-02T13:19:29ZDonepezil for mild cognitive impairment in Parkinson’s disease10.1038/s41598-021-84243-42045-2322https://doaj.org/article/39f7c08a31db49eb80b91afbe4c66e312021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-84243-4https://doaj.org/toc/2045-2322Abstract We investigated the efficacy of donepezil for mild cognitive impairment in Parkinson’s disease (PD-MCI). This was a prospective, non-randomized, open-label, two-arm study. Eighty PD-MCI patients were assigned to either a treatment or control group. The treatment group received donepezil for 48 weeks. The primary outcome measures were the Korean version of Mini-Mental State Exam and Montreal Cognitive Assessment scores. Secondary outcome measures were the Clinical Dementia Rating, Unified Parkinson’s Disease Rating Scale part III, Clinical Global Impression scores. Progression of dementia was assessed at 48-week. Comprehensive neuropsychological tests and electroencephalography (EEG) were performed at baseline and after 48 weeks. The spectral power ratio of the theta to beta2 band (TB2R) in the electroencephalogram was analyzed. There was no significant difference in the primary and secondary outcome measures between the two groups. However, the treatment group showed a significant decrease in TB2R at bilateral frontotemporoparietal channels compared to the control group. Although we could not demonstrate improvements in the cognitive functions, donepezil treatment had a modulatory effect on the EEG in PD-MCI patients. EEG might be a sensitive biomarker for detecting changes in PD-MCI after donepezil treatment.Kyoungwon BaikSeon Myeong KimJin Ho JungYang Hyun LeeSeok Jong ChungHan Soo YooByoung Seok YePhil Hyu LeeYoung H. SohnSeung Wan KangSuk Yun KangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kyoungwon Baik Seon Myeong Kim Jin Ho Jung Yang Hyun Lee Seok Jong Chung Han Soo Yoo Byoung Seok Ye Phil Hyu Lee Young H. Sohn Seung Wan Kang Suk Yun Kang Donepezil for mild cognitive impairment in Parkinson’s disease
description	Abstract We investigated the efficacy of donepezil for mild cognitive impairment in Parkinson’s disease (PD-MCI). This was a prospective, non-randomized, open-label, two-arm study. Eighty PD-MCI patients were assigned to either a treatment or control group. The treatment group received donepezil for 48 weeks. The primary outcome measures were the Korean version of Mini-Mental State Exam and Montreal Cognitive Assessment scores. Secondary outcome measures were the Clinical Dementia Rating, Unified Parkinson’s Disease Rating Scale part III, Clinical Global Impression scores. Progression of dementia was assessed at 48-week. Comprehensive neuropsychological tests and electroencephalography (EEG) were performed at baseline and after 48 weeks. The spectral power ratio of the theta to beta2 band (TB2R) in the electroencephalogram was analyzed. There was no significant difference in the primary and secondary outcome measures between the two groups. However, the treatment group showed a significant decrease in TB2R at bilateral frontotemporoparietal channels compared to the control group. Although we could not demonstrate improvements in the cognitive functions, donepezil treatment had a modulatory effect on the EEG in PD-MCI patients. EEG might be a sensitive biomarker for detecting changes in PD-MCI after donepezil treatment.
format	article
author	Kyoungwon Baik Seon Myeong Kim Jin Ho Jung Yang Hyun Lee Seok Jong Chung Han Soo Yoo Byoung Seok Ye Phil Hyu Lee Young H. Sohn Seung Wan Kang Suk Yun Kang
author_facet	Kyoungwon Baik Seon Myeong Kim Jin Ho Jung Yang Hyun Lee Seok Jong Chung Han Soo Yoo Byoung Seok Ye Phil Hyu Lee Young H. Sohn Seung Wan Kang Suk Yun Kang
author_sort	Kyoungwon Baik
title	Donepezil for mild cognitive impairment in Parkinson’s disease
title_short	Donepezil for mild cognitive impairment in Parkinson’s disease
title_full	Donepezil for mild cognitive impairment in Parkinson’s disease
title_fullStr	Donepezil for mild cognitive impairment in Parkinson’s disease
title_full_unstemmed	Donepezil for mild cognitive impairment in Parkinson’s disease
title_sort	donepezil for mild cognitive impairment in parkinson’s disease
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/39f7c08a31db49eb80b91afbe4c66e31
work_keys_str_mv	AT kyoungwonbaik donepezilformildcognitiveimpairmentinparkinsonsdisease AT seonmyeongkim donepezilformildcognitiveimpairmentinparkinsonsdisease AT jinhojung donepezilformildcognitiveimpairmentinparkinsonsdisease AT yanghyunlee donepezilformildcognitiveimpairmentinparkinsonsdisease AT seokjongchung donepezilformildcognitiveimpairmentinparkinsonsdisease AT hansooyoo donepezilformildcognitiveimpairmentinparkinsonsdisease AT byoungseokye donepezilformildcognitiveimpairmentinparkinsonsdisease AT philhyulee donepezilformildcognitiveimpairmentinparkinsonsdisease AT younghsohn donepezilformildcognitiveimpairmentinparkinsonsdisease AT seungwankang donepezilformildcognitiveimpairmentinparkinsonsdisease AT sukyunkang donepezilformildcognitiveimpairmentinparkinsonsdisease
_version_	1718393265392189440

Donepezil for mild cognitive impairment in Parkinson’s disease

Ejemplares similares